Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Capital Expenditures (2020 - 2025)

Roivant Sciences' Capital Expenditures history spans 6 years, with the latest figure at -$4.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 230.28% year-over-year to -$4.9 million; the TTM value through Dec 2025 reached $10.7 million, up 58.3%, while the annual FY2025 figure was $4.6 million, 232.78% up from the prior year.
  • Capital Expenditures reached -$4.9 million in Q4 2025 per ROIV's latest filing, down from $7.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.2 million in Q4 2021 to a low of -$4.9 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $3.5 million, with a median of $2.8 million recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 687.95% in 2025 against a maximum downside of 230.28% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $11.2 million in 2021, then dropped by 0.94% to $11.1 million in 2022, then plummeted by 90.67% to $1.0 million in 2023, then skyrocketed by 266.7% to $3.8 million in 2024, then tumbled by 230.28% to -$4.9 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Capital Expenditures are -$4.9 million (Q4 2025), $7.8 million (Q3 2025), and $4.0 million (Q2 2025).